Med24
Clinical Medicine 27. 10. 2026 • 2 min read • MedPage Today

Fenebrutinib May Curb Chronic Active Lesions in Multiple Sclerosis

The investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib may curb chronic active lesions in multiple sclerosis (MS), data from phase III trials suggested. Two MRI biomarkers in MS are slowly expanding lesions...

Fenebrutinib May Curb Chronic Active Lesions in Multiple Sclerosis

Fenebrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, demonstrated an ability to reduce chronic active lesions in multiple sclerosis (MS) during phase III trials. Research focused on two imaging biomarkers: slowly expanding lesions (SELs) and paramagnetic rim lesions (PRLs), both indicative of chronic active lesions and key drivers of progressive disease biology.

Key Clinical Findings

In relapsing MS, fenebrutinib showed a 30.5% relative reduction in SEL volume compared with teriflunomide over 96 weeks (P<0.0001). Furthermore, fenebrutinib significantly lowered the odds of a net increase in PRLs by 62% in relapsing MS (OR 0.38, 95% CI 0.22-0.68, P=0.001). In primary progressive MS, fenebrutinib demonstrated a 27.5% relative reduction in SEL volume versus ocrelizumab over 120 weeks (P=0.0006), although the difference in PRL net increase was not statistically significant. Progressive MS biology is present from disease onset regardless of initial presentation, and PRLs are frequently observed early in the disease course.

Sponsored content

Fenebrutinib Characteristics and Trial Results

Fenebrutinib is a non-covalent, reversible, and highly selective BTK inhibitor, having shown lesion reduction in earlier phase II research. Pooled data from FENhance 1 and 2 trials revealed a 55% reduction in annualized relapse rates with fenebrutinib compared to teriflunomide (0.06 vs 0.13, P<0.001) over 96 weeks, alongside a 22.8% reduction in annual total brain volume loss (P<0.001) and a 16% reduction in 12-week composite confirmed disability progression (P=0.04). Transient and reversible liver enzyme elevations were comparable between treatment arms, with one case of Hy’s law observed in each arm, resolving after discontinuation. The FDA accepted a new drug application for fenebrutinib for both relapsing MS and primary progressive MS. SEL analysis utilized T1 and T2 weighted sequences, while PRL analysis was conducted on a subset of participants who underwent 3-Tesla MRIs and susceptibility-sensitive imaging. Approximately 45% of the full sample was included in the PRL analysis.

Original Scientific Source
MedPage Today
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Advertisement